The availability and use of long-acting reversible contraceptives (LARCs), such as levonorgestrel intrauterine systems (LNG-IUSs), have increased in recent times. Areas covered: The authors provide a narrative review of the LNG-IUSs currently available worldwide as female contraceptives (LNG-IUS 13.5, 19.5 and 52 mg). Specific features of the devices and their parameters of efficacy and tolerability were considered as outcomes. Expert opinion: The one-handed 3.8-mm-diameter inserter of LNG-IUS 13.5 mg and 19.5 mg may be particularly suitable in nulliparous women. While LNG-IUSs 13.5, 19.5 mg and LNG 52 mg should be used by women simply looking for an effective contraceptive method for up to 3, 4 or 5 years, LNG-IUS 52 mg has also been approved for the treatment of heavy menstrual bleeding and endometrial protection during hormone replacement therapy. LNG-IUS 52 mg is ideal for women who are experiencing a certain hyperestrogenic hormonal environment, with heavy menstrual bleeding due to hormonal imbalances, adenomyosis or fibroids, in the case of symptomatic endometriosis or for endometrial protection during hormone estrogenic replacement therapy in non-hysterectomized women.

Levonorgestrel-releasing intra-uterine systems as female contraceptives / Grandi, Giovanni; Farulla, Antonino; Sileo, Filomena Giulia; Facchinetti, Fabio. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1744-7666. - 19:7(2018), pp. 677-686. [10.1080/14656566.2018.1462337]

Levonorgestrel-releasing intra-uterine systems as female contraceptives

Grandi, Giovanni;Farulla, Antonino;Sileo, Filomena Giulia;Facchinetti, Fabio
2018

Abstract

The availability and use of long-acting reversible contraceptives (LARCs), such as levonorgestrel intrauterine systems (LNG-IUSs), have increased in recent times. Areas covered: The authors provide a narrative review of the LNG-IUSs currently available worldwide as female contraceptives (LNG-IUS 13.5, 19.5 and 52 mg). Specific features of the devices and their parameters of efficacy and tolerability were considered as outcomes. Expert opinion: The one-handed 3.8-mm-diameter inserter of LNG-IUS 13.5 mg and 19.5 mg may be particularly suitable in nulliparous women. While LNG-IUSs 13.5, 19.5 mg and LNG 52 mg should be used by women simply looking for an effective contraceptive method for up to 3, 4 or 5 years, LNG-IUS 52 mg has also been approved for the treatment of heavy menstrual bleeding and endometrial protection during hormone replacement therapy. LNG-IUS 52 mg is ideal for women who are experiencing a certain hyperestrogenic hormonal environment, with heavy menstrual bleeding due to hormonal imbalances, adenomyosis or fibroids, in the case of symptomatic endometriosis or for endometrial protection during hormone estrogenic replacement therapy in non-hysterectomized women.
11-apr-2018
19
7
677
686
Levonorgestrel-releasing intra-uterine systems as female contraceptives / Grandi, Giovanni; Farulla, Antonino; Sileo, Filomena Giulia; Facchinetti, Fabio. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1744-7666. - 19:7(2018), pp. 677-686. [10.1080/14656566.2018.1462337]
Grandi, Giovanni; Farulla, Antonino; Sileo, Filomena Giulia; Facchinetti, Fabio
File in questo prodotto:
File Dimensione Formato  
GrandiG2018LNG-IUS.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 948.86 kB
Formato Adobe PDF
948.86 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1168125
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 29
social impact